No connection

Search Results

IART vs KURA

IART
Integra LifeSciences Holdings Corporation
NEUTRAL
Price
$9.90
Market Cap
$771.6M
Sector
Healthcare
AI Confidence
85%
KURA
Kura Oncology, Inc.
BEARISH
Price
$8.67
Market Cap
$765.8M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
IART
--
KURA
--
Forward P/E
IART
3.86
KURA
-3.55
P/B Ratio
IART
0.74
KURA
4.37
P/S Ratio
IART
0.47
KURA
11.35
EV/EBITDA
IART
8.54
KURA
-0.39

Profitability

Gross Margin
IART
56.23%
KURA
-272.14%
Operating Margin
IART
12.44%
KURA
-497.62%
Profit Margin
IART
-31.58%
KURA
0.0%
ROE
IART
-39.9%
KURA
-94.82%
ROA
IART
2.39%
KURA
-25.33%

Growth

Revenue Growth
IART
-1.7%
KURA
-67.8%
Earnings Growth
IART
--
KURA
--

Financial Health

Debt/Equity
IART
1.95
KURA
0.12
Current Ratio
IART
2.54
KURA
6.06
Quick Ratio
IART
1.19
KURA
5.81

Dividends

Dividend Yield
IART
--
KURA
--
Payout Ratio
IART
0.0%
KURA
0.0%

AI Verdict

IART NEUTRAL

IART presents as a classic deep-value turnaround candidate with a stable Piotroski F-Score of 6/9, indicating reasonable operational health despite severe price depreciation. The company is trading at a significant discount to book value (P/B 0.74) and possesses a very low forward P/E of 3.86, suggesting the market has over-priced the risk. However, negative net profit margins (-31.58%) and stagnant revenue growth (-1.70%) offset the valuation appeal. The stark contrast between the current price ($9.90) and the analyst target ($15.57) indicates potential upside, but the bearish technical trend remains a primary headwind.

Strengths
Deep value valuation with P/B of 0.74 and P/S of 0.47
Strong short-term liquidity with a Current Ratio of 2.54
Stable financial health baseline (Piotroski F-Score 6/9)
Risks
Severe long-term price erosion (-85.7% over 5 years)
Negative net profit margins (-31.58%) impacting bottom-line stability
Stagnant to declining revenue growth (YoY -1.70%)
KURA BEARISH

KURA presents a contradictory profile with a stable Piotroski F-Score of 6/9 and exceptional liquidity (Current Ratio 6.06), yet suffers from severe fundamental decay. The company has experienced a catastrophic revenue decline of -67.80% YoY and has missed earnings estimates in four consecutive quarters with an average surprise of -50.91%. While the analyst target price of $31.82 suggests significant upside, this is decoupled from the current financial reality of negative gross margins (-272.14%) and bearish insider activity. The stock is currently a speculative play on pipeline success rather than a value or growth investment based on existing data.

Strengths
Strong liquidity position with a Current Ratio of 6.06
Very low leverage with a Debt/Equity ratio of 0.12
Stable Piotroski F-Score (6/9) indicating baseline operational stability
Risks
Severe revenue contraction (-67.80% YoY and Q/Q)
Consistent earnings misses (0/4 beats in the last year)
Deeply negative profitability (Operating Margin -497.62%)

Compare Another Pair

IART vs KURA: Head-to-Head Comparison

This page compares Integra LifeSciences Holdings Corporation (IART) and Kura Oncology, Inc. (KURA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile